Alligator Bioscience AB (FRA:7AL0) ROC (Joel Greenblatt) %: 859.81% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7AL0 Alligator Bioscience AB FRA:7AL0
41 GF Score
Price €0.00
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB ROC (Joel Greenblatt) %?

Alligator Bioscience AB FRA:7AL0 41 ROC (Joel Greenblatt) % is 859.81% as of Mar. 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 41/100. The stock has 7 warning signs investors should review. Among 1,323 Biotechnology companies, Alligator Bioscience AB ranks better than 50.42% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Alligator Bioscience AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 859.81%.

The historical rank and industry rank for Alligator Bioscience AB's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:7AL0' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1873.22   Med: -771.56   Max: -241.04
Current: -290.85

During the past 12 years, Alligator Bioscience AB's highest ROC (Joel Greenblatt) % was -241.04%. The lowest was -1873.22%. And the median was -771.56%.

FRA:7AL0's ROC (Joel Greenblatt) % is ranked better than
50.42% of 1323 companies
in the Biotechnology industry
Industry Median: -297.52 vs FRA:7AL0: -290.85

Alligator Bioscience AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -0.50% per year.


Alligator Bioscience AB  (FRA:7AL0) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Alligator Bioscience AB ROC (Joel Greenblatt) % Related Terms


Alligator Bioscience AB ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB ROC (Joel Greenblatt) % Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -727.98 -887.52 -1,039.85 -1,827.90 -299.31

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 663.53 2,454.70 -1,342.93 -3,615.22 859.81

FRA:7AL0 vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's ROC (Joel Greenblatt) % falls into.


FRA:7AL0
41GF Score
Alligator Bioscience AB FRA:7AL0
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.371) - (0.561 + 0 + 5.007)
=-5.197

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + -0.00099999999999945) - (0.414 + 0 + 1.569)
=-1.984

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Alligator Bioscience AB for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.38/( ( (0.172 + max(-5.197, 0)) + (0.149 + max(-1.984, 0)) )/ 2 )
=1.38/( ( 0.172 + 0.149 )/ 2 )
=1.38/0.1605
=859.81 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 859.81% mean?
Alligator Bioscience AB (FRA:7AL0) has a ROC (Joel Greenblatt) % of 859.81% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #656 out of 1323 companies in the Biotechnology industry, placing it in the top 49.6%.
Is Alligator Bioscience AB's ROC (Joel Greenblatt) % too high?
Alligator Bioscience AB's current ROC (Joel Greenblatt) % is 859.81%. Based on the distribution chart, Alligator Bioscience AB ranks #656 out of 1323 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alligator Bioscience AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #656 out of 1323 companies for ROC (Joel Greenblatt) %. This puts Alligator Bioscience AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current ROC (Joel Greenblatt) % is 859.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current ROC (Joel Greenblatt) % of 859.81%. The current ROC (Joel Greenblatt) % is 859.81%. Alligator Bioscience AB's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current ROC (Joel Greenblatt) % is 859.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
41GF Score

Get the complete analysis for FRA:7AL0

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price